This is a study to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment.
ReLOAD: Regorafenib and Lorigerlimab
Kathryn Aziz2025-09-22T20:16:57+00:00This is a study to assess the effects of the drugs Regorafenib and Lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy.
Fruquintinib and Tislelizumab
Kathryn Aziz2025-09-22T20:18:20+00:00This is an upcoming trial to study Fruquitinib (VEGFR inhibitor) in combination with Tislelizumab (PD-1 inhibitor).